Division of Pediatric Allergy and
Clinical Immunology, Department of Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada. RATIONALE: Skin testing or specific IgE immunoassays have limited clinical utility for the diagnosis of cephalosporin allergy. We aimed to assess oral cephalosporin antibiotic allergy in children through the use of a graded oral challenge (GOC). METHODS: All children referred to the Montreal Children's Hospital for suspected cephalosporin allergy were recruited between March 2013 and March 2018. Data were collected through a standardized questionnaire on demographics, clinical characteristics, and management. A GOC (10% and 90% of the oral dose) was conducted to cephalosporin antibiotics excluding ceftriaxone. Multivariate logistic regression was used to estimate factors associated with a positive GOC. RESULTS: Among 101 patients with a reported allergy to cephalosporins, 80.20% reported a reaction to cefprozil, 5.94% to cefixime, 7.92% to cephalexin and 5.94% to other cephalosporins (cefuroxime, cefazolin, cefdinir). RATIONALE: The population-based incidence of penicillin-and clindamycin-associated anaphylaxis and serious cutaneous adverse reactions (SCARs) is uncertain. METHODS: All penicillin and clindamycin use between 1-1-2009 and 12-31-2017 in Kaiser Permanente Southern California, all anaphylaxis coded the same day as a parenteral or within 1 day of an oral exposure, and all SCARs coded within 30 days were identified. Cases were audited to verify if anaphylaxis or SCAR occurred and was uniquely penicillin-or clindamycin-associated. RESULTS: There were 6,144,422 unique individuals, mean age 34.25 6 20.85 years, 52.16% females, with at least one healthcare visit during the 9-year study interval, for a total of 37,387,312 patient-years. 2,115,406 individuals were exposed to 4,558,196 courses of oral penicillins, 192,925 individuals to 285,894 courses of parenteral penicillins, 412,764 individuals to 605,595 courses of oral clindamycin, and 64,833 individuals to 79,865 courses of parenteral clindamycin. There were 22 cases (1 in 207,191) of oral penicillin-associated anaphylaxis, 13 females, 16 amoxicillin-, 4 amoxicillin-clavulanate-, and 2 dicloxacillin-associated. There were 3 cases (1 in 95,298) of parenteral penicillin-associated anaphylaxis, 2 males, 2 piperacillin-tazobactam-and 1 ampicillin-sulbactam-associated. There were 2 clindamycin-associated anaphylaxis cases, both females, 1 (1 in 605,595) oral and 1 (1 in 79,865) parenteral. There were 2 (1 in 2,422,045) penicillin-associated SCAR cases, 1 amoxicillin-and 1 ampicillin-sulbactam-associated, but both with co-trimoxazole co-exposure within 45 days. There was 1 (1 in 685,460) clindamycin-associated SCAR. CONCLUSIONS: Parenteral penicillin-associated anaphylaxis is more likely than oral (p < 0.001). Clindamycin-associated anaphylaxis is extremely rare. SCARs are extremely rare with both penicillins and clindamycin.
